Reviva Pharmaceuticals I... (RVPH)
Reviva Pharmaceuticals Statistics
Share Statistics
Reviva Pharmaceuticals has 46.74M shares outstanding. The number of shares has increased by 56.22% in one year.
| Shares Outstanding | 46.74M |
| Shares Change (YoY) | 56.22% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 22.87% |
| Shares Floating | 41.78M |
| Failed to Deliver (FTD) Shares | 6.91K |
| FTD / Avg. Volume | 0.66% |
Short Selling Information
The latest short interest is 2.92M, so 6.27% of the outstanding shares have been sold short.
| Short Interest | 2.92M |
| Short % of Shares Out | 6.27% |
| Short % of Float | 7.02% |
| Short Ratio (days to cover) | 5.86 |
Valuation Ratios
The PE ratio is -2.01 and the forward PE ratio is -1.08. Reviva Pharmaceuticals's PEG ratio is 0.04.
| PE Ratio | -2.01 |
| Forward PE | -1.08 |
| PS Ratio | 0 |
| Forward PS | 0.3 |
| PB Ratio | 73.84 |
| P/FCF Ratio | -1.79 |
| PEG Ratio | 0.04 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Reviva Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.01, with a Debt / Equity ratio of 0.56.
| Current Ratio | 1.01 |
| Quick Ratio | 1.01 |
| Debt / Equity | 0.56 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.01 |
| Interest Coverage | -1665.07 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-2.14M |
| Employee Count | 14 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 19.51K |
| Effective Tax Rate | -0.07% |
Stock Price Statistics
The stock price has increased by -71.91% in the last 52 weeks. The beta is 0.05, so Reviva Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.05 |
| 52-Week Price Change | -71.91% |
| 50-Day Moving Average | 1.07 |
| 200-Day Moving Average | 1.3 |
| Relative Strength Index (RSI) | 49.79 |
| Average Volume (20 Days) | 1.05M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -30.8M |
| Net Income | -29.92M |
| EBITDA | -29.88M |
| EBIT | -29.88M |
| Earnings Per Share (EPS) | -0.9 |
Balance Sheet
The company has 13.48M in cash and 458.15K in debt, giving a net cash position of 13.02M.
| Cash & Cash Equivalents | 13.48M |
| Total Debt | 458.15K |
| Net Cash | 13.02M |
| Retained Earnings | -164.27M |
| Total Assets | 15.5M |
| Working Capital | 81.86K |
Cash Flow
In the last 12 months, operating cash flow was -33.54M and capital expenditures 0, giving a free cash flow of -33.54M.
| Operating Cash Flow | -33.54M |
| Capital Expenditures | 0 |
| Free Cash Flow | -33.54M |
| FCF Per Share | -1.01 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RVPH does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for RVPH is $9.5, which is 1031% higher than the current price. The consensus rating is "Buy".
| Price Target | $9.5 |
| Price Target Difference | 1031% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | -17.89 |
| Piotroski F-Score | 0 |